

November 7, 2005

Contact Information:

Corporate Communications

Astellas Pharma Inc.

Phone: +81-3-3244-3201

Astellas Revises Its Dividends Forecasts For Current Fiscal Year

Japan, November 7, 2005 – Astellas Pharma Inc. (“Astellas”, headquarters: Tokyo, president and CEO: Toichi Takenaka) announced today that it decided to revise the dividends forecasts for the fiscal year ending March 31, 2006 at the meeting of Board of Directors held today.

1. The reason of the revision

Astellas is, committed to secure proper profit level by investing in ethical pharmaceutical business and strengthening its management base as well as rewarding the shareholders comprehensively by dividends and share buyback. The level of dividends is decided considering consolidated business results, prospect of medium and long term growth of the business, Dividends-on-Equity(DOE) Ratio, etc. placing the stable and sustainable increase of the dividends as the basic policy. The forecast for year-end dividends is revised this time to 40 yen per share, which is 10 yen per share increase from the previous forecast, as the business of Astellas for this fiscal year is expected to stably grow. As a result, the forecast for full year dividends is also revised to 70 yen per share, including interim year dividends.

2. Details of the revision

	Interim Dividends (Actual)	Year-end Dividends (Forecasts)	Full Year Dividends
Previous Forecasts (May 17, 2005)	30.00 yen	30.00 yen	60.00 yen
New Forecasts	30.00 yen	40.00 yen	70.00yen
(For Information: former Yamanouchi) Previous Year's Dividends	15.00 yen	16.00 yen	31.00 yen

Per a Common Stock

#####